Clinical trials: ACS - Acute Coronary Syndrome
Cardiogenic Shock
Testing the Value of Novel Strategy and Its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock
Cardiogenic shock (CGS) affects up to 10% of patients suffering acute coronary syndrome. It has a 30 day mortality of 45-50%. No pharmacological nor intervention/device trials have had any impact on this mortality in the last 20…
- Trial name
- EUROSHOCK (NCT03813134)
- Testing
- Percutaneous coronary intervention (PCI), Pharmacological Support, VA-ECMO
- Where
- 47 sites in Austria, Belgium and 6 more
- Volunteers
- 428 people
- Sponsor
- University of Leicester
Acute Coronary Syndrome, Angina Pectoris
DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity in an All Comers Population
The introduction of drug-eluting stents (DES) in the treatment of coronary artery disease has led to a significant reduction in morbidity but there are further demands on DES performance.
- Conditions
- Acute Coronary Syndrome, Angina Pectoris, Angina, Unstable, Myocardial Infarction
- Trial name
- DUTCH PEERS (NCT01331707)
- Testing
- Resolute Integrity (Zotarolimus-eluting stent), Promus Element (Everolimus-eluting stent)
- Where
- 4 sites in Netherlands
- Volunteers
- 1,811 people
- Sponsor
- Foundation of Cardiovascular Research and Education Enschede
Acute Coronary Syndrome, Coronary Artery Disease
Full-dose Atorvastatin After Acute Coronary Syndrome (ACS) in Non-revascularisable Coronary Artery Disease
This study was designed to test the hypothesis that the addition of full-dose atorvastatin (80 mg/day) to conventional medical treatment could reduce ischaemic recurrences after non-ST-elevation acute myocardial infarction…
- Trial name
- APRIRE (NCT01187992)
- Testing
- Atorvastatin
- Where
- Italy
- Volunteers
- 290 people
- Sponsor
- San Filippo Neri General Hospital
Microvascular Obstruction (MVO), Multivessel Coronary Artery Disease
For Patients With Myocardial Infarction and Multiple Vessel: Testing if Ultrasound (UFR) Can Guide All Needed Treatment in One Procedure, Avoiding a Return Hospital Visit for a Second Operation.
Brief Summary The Purpose of the Study : The purpose of this study is to find a safe and reliable "one-stop" solution for treating heart attack patients who have multiple blocked arteries.
- Conditions
- Microvascular Obstruction (MVO), Multivessel Coronary Artery Disease, ACS (Acute Coronary Syndrome), ST Elevation Myocardial Infarction (STEMI)
- Trial name
- ACT-EVOLVE (NCT07264881)
- Testing
- IVUS-based Fractional Flow Reserve (UFR), Invasive Coronary Physiology Measurement (FFR/RFR/IMR), Cardiac Magnetic Resonance (CMR)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing Anzhen Hospital
Stable Angina, Acute Coronary Syndrome
Novasight Hybrid Intravascular Ultrasound and Optical Coherence Tomography System (IVUS OCT)
Collection of coronary images with a hybrid IVUS OCT system.
- Trial name
- NCT03484975
- Testing
- Observation group
- Where
- Canada
- Volunteers
- 23 people
- Sponsor
- Conavi
Acute Coronary Syndrome, Ischemic Stroke
Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects
This study is designed to evaluate the pharmacokinetics, pharmacodynamics and safety in healthy subjects with multiple administration of Tiprogrel.
- Trial name
- NCT06584812
- Testing
- Tiprogrel, Clopidogrel, Ticagrelor
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Tianjin Institute of Pharmaceutical Research Co., Ltd
Acute Coronary Syndromes, Non ST Elevation Myocardial Infarction
Sub Lingual Versus Traditional Oral Administration of Ticagrelor in Acute Coronary Syndrome/Non ST-elevation Myocardial Infarction - A Platelet Reactivity Study
Our goal is to examine sub lingual versus traditional oral administration of ticagrelor in ACS/non ST-elevation Myocardial Infarction (NSTEMI) patients on platelet reactivity.
- Trial name
- NCT02402400
- Testing
- Sub Lingual Ticagrelor
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Sheba Medical Center
Acute Coronary Syndrome
The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man
Background: Coronary heart disease is the most common cause of death in industrialized countries. Revascularisation by percutaneous coronary angioplasty or thrombolysis is the main principle for treatment of the acute coronary…
- Trial name
- NCT02120092
- Testing
- Clopidogrel, Ticagrelor, ASA
- Where
- Austria
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Acute Coronary Syndrome
Polymer Free Stent in Acute Coronary Syndrome
To evaluate the short term out comes of the polymer free stents in patients presented with non ST elevation acute coronary syndrome (which include ST depression myocardial infarction and unstable angina ) after percutaneous…
- Trial name
- NCT03878966
- Testing
- Inserting polymer free drug eluting stent in the coronary arteries
- Volunteers
- 30 people
- Sponsor
- Assiut University
Atrial Fibrillation, Syncope
Evaluation of Ambulatory Monitoring of Patients After High-risk Acute Coronary Syndrome Using Two Different Systems: Biomonitor-2 and Kardia Mobile
The objective of the study is to evaluate the efficacy of monitoring after discharge of patients with high-risk acute coronary syndrome.
- Conditions
- Atrial Fibrillation, Syncope, Tachycardia, Arrhythmias, Cardiac
- Trial name
- Monitor- ACS (NCT03940066)
- Testing
- Biomonitor-2 and Kardia mobile, No Intervention
- Where
- Spain
- Volunteers
- 169 people
- Sponsor
- Fundación EPIC
Patients Admitted With the Diagnosis of ST-elevation Acute Coronary Syndrome
inflAmmatory maRkers in Blood and Thrombus Aspirated From Patients With acutE myocaRdial Infarction With St-segment elevAtion
The prognostic value of inflammatory markers in acute coronary syndrome has been extensively demonstrated, however it is still unknown whether there is an association between circulating and local (thrombus) inflammatory…
- Trial name
- ARTERIA (NCT01757886)
- Testing
- Biomarkers to analyze both intracoronary thrombi as blood
- Where
- 3 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Fundación Canaria Rafael Clavijo para la Investigación Biomédica
Acute Coronary Syndrome
Phase III Acute Coronary Syndrome
The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome
- Trial name
- APPRAISE-2 (NCT00831441)
- Testing
- Apixaban
- Where
- 1,012 sites in United States, Argentina and 38 more
- Volunteers
- 7,484 people
- Sponsor
- Bristol-Myers Squibb
Acute Coronary Syndromes (ACS), Hypercholesterolemia
Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome
The goal of this clinical trial is to evaluate whether triple lipid-lowering therapy (atorvastatin, ezetimibe, and bempedoic acid) is more effective than dual therapy (atorvastatin and ezetimibe) in reducing LDL cholesterol…
- Trial name
- TLD-ACS (NCT07508254)
- Testing
- Atorvastatin 40 Mg Oral Tablet, Ezetimibe 10 mg, Bempedoic Acid 180 MG Oral Tablet
- Where
- Pakistan
- Volunteers
- 120 people
- Sponsor
- Punjab Institute of Cardology
Acute Coronary Syndromes, Depression
Integrating Depression Care in Acute Coronary Syndromes Care in China
The overall goal of this study is to develop, pilot test, implement, and evaluate a nurse-coordinated depression care model integrated into the care of Acute Coronary Syndromes (ACS) patients with rigorous assessment of…
- Trial name
- I-Care (NCT02195193)
- Testing
- Integrated care
- Where
- China
- Volunteers
- 4,043 people
- Sponsor
- The George Institute for Global Health, China
Vessel Restenosis
Dexamethasone-Eluting Stent in Acute Coronary Syndrome to Prevent Restenosis
The major obstacle of the long- termed success of percutaneous coronary intervention (PCI) is the restenosis. Restenosis results from complex pathophysiological response of the vascular tissue to the balloon injury.
- Trial name
- NCT00190099
- Testing
- Dexamethasone-Eluting Stent
- Volunteers
- 40 people
- Sponsor
- Far Eastern Memorial Hospital
Coronary Arterial Disease (CAD), ACS (Acute Coronary Syndrome)
Impact of CYP2C19 Genotype-guided Approach in Antiplatelet Therapy on Platelet Reactivity Index Among Coronary Artery Disease (CAD) Patients
The goal of this clinical trial is to learn if the pilot intervention of CYP2C19 genotype-guided antiplatelet therapy works to reduce the occurrence of cardiovascular events after Percutaneous Coronary Intervention (PCI) done in…
- Conditions
- Coronary Arterial Disease (CAD), ACS (Acute Coronary Syndrome), SCAD
- Trial name
- NCT06759272
- Testing
- CYP2C19 genotype-guided antiplatelet therapy
- Where
- Malaysia
- Volunteers
- 120 people
- Sponsor
- Nur Hafizah Annezah binti Utuh
Acute Coronary Syndrome
Symptoms of Acute Coronary Syndrome in Medical Regulation
The main objective was to analyze the impact of the gender of the attending physician in the differences in the management of ST+ ACS between men and women.
- Trial name
- SCAST+ (NCT05902130)
- Testing
- symptoms of a myocardial infarction
- Where
- France
- Volunteers
- 208 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
Acute Coronary Syndrome
Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina
The purpose of this study is to determine if veliflapon (DG-031)can prevent a heart attack or stroke in African American patients with a history of unstable angina or myocardial infarction.
- Trial name
- NCT00353067
- Testing
- veliflapon (DG-031)
- Where
- 11 sites in United States
- Volunteers
- 3,450 people
- Sponsor
- deCODE genetics
Acute Coronary Syndrome
Relationship Between Inflammatory (Hs-CRP, Neutrophil-to-Lymphocyte Ratio) and Cardiac (Troponin) Biomarkers, and Cardiac Dysfunction in Acute Coronary Syndrome.
Acute Coronary Syndrome (ACS) remains a leading cause of morbidity and mortality worldwide, accounting for a significant proportion of cardiovascular-related deaths.
- Trial name
- NCT07551102
- Volunteers
- 144 people
- Sponsor
- Assiut University
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Optimized Antiplatelet Therapy on the Prognosis of ACS Patients With Non-predominant Coronary Artery Disease After PCI
The study is to evaluate the effect of optimized 12-month step-down antiplatelet therapy (APT) compared with standard 12-month dual antiplatelet therapy in clinical net adverse events, cardiovascular and cerebrovascular adverse…
- Trial name
- NCT04338919
- Testing
- Percutaneous coronary intervention, Ticagrelor plus aspirin
- Where
- China
- Volunteers
- 2,020 people
- Sponsor
- Fujian Medical University